Alpha Teknova Inc

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. Its primary products include pre-poured media plates for cell growth and cloning, liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company also offers lab essentials, which provide chemical formulations for biological research and drug discovery, and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. It serves the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Biotech & Genomic Medicine▲

Teknova raises 2026 revenue guidance to $45M-$47M and targets free cash outflow below $8M

Alpha Teknova raised its full-year 2026 revenue guidance to between $45 million and $47 million, up from a prior range of $42 million to $44 million, and now expects free cash outflow of less than $8 million for the year. CEO Stephen Gunstream reported that second-quarter revenue exceeded $12 million, the highest in the company's 30-year history, with growth across all major target segments except cell and gene therapy. CFO Matthew Lowell said gross margin is expected in the mid- to upper 30s percentage range for 2026, while operating expenses will be at least $8 million per quarter through year-end. The company also launched Build-Tek, an AI-powered custom order configurator, and maintained its 2027 revenue target in the low $50 million range, with adjusted EBITDA positivity expected before the end of 2027.

TKNO ▲

Biotech & Genomic Medicine ▲

Seeking Alpha·44dRead more →